Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402766 · ClinicalTrials.gov registry record · Phase 1
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00402766: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00402766 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00402766, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Primary Objective: * To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma. Secondary Objectives: * To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by: * histologic analysis of biopsy tissue * by non-invasive assessments of tumor vascularity performed before, during and after treatment * electron microscopy analysis of endothelial cell architecture after patient treatment with imatinib mesylate * To explore the effects of cisplatin, imatinib mesylate, and pemetrexed on surrogate markers in serum. * To assess the rate of response to therapy. * To determine the doses of the combination regimen of cisplatin, imatinib mesylate, and pemetrexed that enables de-phosphorylation of platelet derived growth factor receptor (PDGF-R) on malignant mesothelioma tumor cells. * To determine the pharmacokinetic interaction between agents in this combination regimen.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Dexamethasone
- DRUG Imatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2006-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402766
The ClinicalTrials.gov registry entry for NCT00402766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00402766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402766 about?
NCT00402766 is a clinical study titled "Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma". Primary Objective: * To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma. Secondary Objectives: * To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by: * histo...
What is the current status of trial NCT00402766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2006-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00402766?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Dexamethasone (DRUG), Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT00402766?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.